Pertuzumab and Trastuzumab hyaluronidase (Phesgo)

Generic name: pertuzumab/trastuzumab/hyaluronidase-zzxf
Brand name: Phesgo

General information

A combination of pertuzumab and trastuzumab, to be given by subcutaneous injection

2020-06-29: Initial approval in combination with chemotherapy as neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. (Based on NeoSphere, TRYPHAENA, BERENICE, APHINITY, FeDeriCa)
2020-06-29: Initial approval in combination with chemotherapy as adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence. (Based on NeoSphere, TRYPHAENA, BERENICE, APHINITY, FeDeriCa)
2020-06-29: Initial approval in combination with docetaxel for treatment of patients with HER2 positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. (Based on CLEOPATRA & FeDeriCa)

2023-09-25: New combination drugs with a new active ingredient indicated for the treatment of HER2-positive breast cancer.
2023-09-25: New combination drugs with a new active ingredient indicated for the treatment of unresectable advanced or recurrent HER2-positive colon or rectal cancer that has progressed after cancer chemotherapy.